en · de · es · fr · pt
cjc-1295-notes.peptides6908.com › Data › Background And Molecular Design — Practical Notes

Background And Molecular Design — Practical Notes

By Editorial Desk · published 2025-10-05 · last reviewed 2025-11-07 · Data

Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-11-07. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Analytical Measurement And Stability

Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.

Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.

Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.

Cjc-1295 at a glance

PropertyValueNotes
AppearanceWhite to off white powderTypical lyophilized form
Water solubilitySolubleMay need a small organic co-solvent
Purity assessmentChromatographic peak areaMost certificates report a percentage figure
Storage temperatureMinus 20 C or lowerDry, dark, sealed container
Identity checkElectrospray mass spectrometryCompared against theoretical mass

Molecular Background and Naming

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Related pages on this site

Compound Identity and Development History

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

Handling, Stability and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.

Identity and Naming History

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Reference notes

=== East Africa === Italy joined the war on Germany's side on 10 June 1940, opening the East African Campaign and the Desert War in North Africa. A Rhodesian-led force of irregulars from the Somaliland Camel Corps—based in British Somaliland, on the Horn of Africa's north coast—took part in one of the first clashes between British and Italian forces when it exchanged fire with an Italian banda (irregular company) around dawn on 11 June. Two days later three Caproni bombers of the Regia Aeronautica attacked Wajir, one of No. 237 Squadron's forward airstrips, damaging two Rhodesian aircraft.

=== Temporal arteritis === About 20% of people who are diagnosed with polymyalgia rheumatica also have temporal arteritis (also called giant cell arteritis), and about 50% of people with temporal arteritis have polymyalgia rheumatica. Some symptoms of temporal arteritis include headaches, scalp tenderness, jaw or facial soreness, distorted vision, or aching in the limbs caused by decreased blood flow, and fatigue.

Dexamethasone is a fluorinated glucocorticoid medication used to treat rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive pulmonary disease (COPD), croup, brain swelling, eye pain following eye surgery, superior vena cava syndrome (a complication of some forms of cancer), and along with antibiotics in tuberculosis. In adrenocortical insufficiency, it may be used in combination with a mineralocorticoid medication such as fludrocortisone. In preterm labor, it may be used to improve outcomes in the baby. It may be given by mouth, as an injection into a muscle, as an injection into a vein, as a topical cream or ointment for the skin or as a topical ophthalmic solution to the eye. The effects of dexamethasone are frequently seen within a day and last for about three days. The long-term use of dexamethasone may result in thrush, bone loss, cataracts, easy bruising, or muscle weakness. It is in pregnancy category C in the United States, meaning that it should only be used when the benefits are predicted to be greater than the risks. In Australia, the oral use is category A, meaning it has been frequently used in pregnancy and not been found to cause problems to the baby. It should not be taken when breastfeeding. Dexamethasone has anti-inflammatory and immunosuppressant effects. Dexamethasone was first synthesized in 1957 by Philip Showalter Hench and was approved for medical use in 1958. It is on the World Health Organization's List of Essential Medicines.

=== Aspartate === The biosynthesis of aspartate frequently involves the transamination of oxaloacetate. The enzyme aspartokinase, which catalyzes the phosphorylation of aspartate and initiates its conversion into other amino acids, can be broken up into 3 isozymes, AK-I, II and III. AK-I is feed-back inhibited by threonine, while AK-II and III are inhibited by lysine. As a sidenote, AK-III catalyzes the phosphorylation of aspartic acid that is the committed step in this biosynthetic pathway. Aspartate kinase becomes downregulated by the presence of threonine or lysine.

Sources: en.wikipedia.org

Reference notes

In molecular cloning, a vector is any particle (e.g., plasmids, cosmids, Lambda phages) used as a vehicle to artificially carry a foreign nucleic sequence – usually DNA – into another cell, where it can be replicated and/or expressed. A vector containing foreign DNA is termed recombinant DNA. The four major types of vectors are plasmids, viral vectors, cosmids, and artificial chromosomes. Of these, the most commonly used vectors are plasmids. Common to all engineered vectors are the origin of replication, a multicloning site, and a selectable marker. The vector itself generally carries a DNA sequence that consists of an insert (in this case the transgene) and a larger sequence that serves as the "backbone" of the vector. The purpose of a vector which transfers genetic information to another cell is typically to isolate, multiply, or express the insert in the target cell. All vectors may be used for cloning and are therefore cloning vectors, but there are also vectors designed specially for cloning, while others may be designed specifically for other purposes, such as transcription and protein expression. Vectors designed specifically for the expression of the transgene in the target cell are called expression vectors, and generally have a promoter sequence that drives the expression of the transgene. Simpler vectors called transcription vectors are only capable of being transcribed but not translated: they can be replicated in a target cell but not expressed, unlike expression vectors. Transcription vectors are used to amplify their insert.

Polling indicated that the majority of voters support a ceasefire and American mediation in the Gaza war. According to a YouGov poll in March 2024, 52% of Americans supported stopping weapons shipments to Israel, coming largely from Americans who voted for Biden in 2020 (62% support) and people who did not vote in 2020 (60%). 55% of Americans who voted for Trump in 2020 opposed halting weapons shipments, while 30% supported the measure. Republicans generally supported arms to Israel, while Democrats were divided on the issue. Harris largely continued Biden's approach to the Israeli–Palestinian conflict, although she was seen as more sympathetic to Palestinians than Biden or Trump. During the Gaza war, Harris supported Israel's offensive, saying "the threat Hamas poses to the people of Israel must be eliminated". By March 2024, Harris was increasingly critical of Israel, calling for a ceasefire and two-state solution, and opposing the Rafah offensive, though still supporting the war overall. In the Democratic primaries, the Uncommitted National Movement led a protest campaign against Biden and later Harris over the war, calling for a ceasefire and arms embargo on Israel. It received over 700,000 votes and 36 delegates. Harris engaged with Uncommitted and Arab-American leaders, but refused to change her position. Harris argued for continued weapons shipments to Israel, saying it had a right to defend itself. Uncommitted ultimately encouraged its supporters to vote for Harris, though many were reluctant.

==== Eyelashes ==== The FP receptor agonist, bimatoprost, in the form of an 0.03% ophthalmic solution termed Latisse, is approved by the US Food and Drug Administration to treat hypotrichosis of the eyelashes, in particular to darken and lengthen eyelashes for cosmetic purposes. Also, bimatoprost may be used to treat small or underdeveloped eyelashes.

Supervised injection sites are legally sanctioned, medically supervised facilities designed to provide a safe, hygienic, and stress-free environment for people who use substances. The facilities provide sterile injection equipment, information about substances and basic health care, treatment referrals, and access to medical staff. Opioid agonist therapy (OAT) is the medical procedure of using a harm-reducing opioid that produces significantly less euphoria, such as methadone or buprenorphine to reduce opioid cravings in people who use illegal opioids, such as heroin; buprenorphine and methadone are taken under medical supervision. Another approach is heroin assisted treatment, in which medical prescriptions for pharmaceutical heroin (diacetylmorphine) are provided to people who are dependent on heroin. Media campaigns inform drivers of the dangers of driving drunk. Most people who recreationally consume alcohol are now aware of these dangers and safe ride techniques like 'designated drivers' and free taxicab programmes are reducing the number of drunk-driving crashes. Many schools now provide safer sex education to teen and pre-teen students, who may engage in sexual activity. Since some adolescents are going to have sex, a harm-reductionist approach supports a sexual education which emphasizes the use of protective devices like condoms and dental dams to protect against unwanted pregnancy and the transmission of STIs. Since 1999, some countries have legalized or decriminalized prostitution, such as Germany (2002) and New Zealand (2003).

Sunless tanning refers to the effect of a suntan without exposure to the Sun. Sunless tanning involves the use of oral agents (carotenids), or creams, lotions or sprays applied to the skin. Skin-applied products may be skin-reactive agents or temporary bronzers (colorants). Sunless tanning has emerged as an alternative to UV exposure (from sunlight or indoor tanning), which has been linked to increased risk of skin cancer. The chemical compound dihydroxyacetone (DHA) is used in sunless tanning products in concentrations of 3%-5%. DHA concentration is adjusted to provide darker and lighter shades of tan. The reaction of keratin protein present in skin and DHA is responsible for the production of pigmentation.

Sources: en.wikipedia.org

Notes from published material

During the lockdown Gavin suggested, 'Why don't we record these things so we've at least got studio recordings of this material?' That doesn't mean we're going to make a new album or it's ever gonna come out, but we have started this process." In a November 2024 interview with Louder Sound, Jakszyk was questioned about the band's future and mentioned the possibility of new studio recordings being released, stating: "The honest answer is, you'll have to ask Robert. It's all in his hands. He's retired a million times before, but he is 78. One of the things we have been doing of late is recording studio versions of the new material [only previously played live]. We've used the live recordings as a template, and I've done guitars, overdubs and backing vocals. Whether that comes out as a King Crimson album or whether it lies in the vaults, I don't know." Eight months later, in a July 2025 interview with Goldmine magazine, Jakszyk stated that "as we speak, we're doing a King Crimson studio album" and confirmed that it featured the most recent band line-up. He cautioned "when that will come out and what format or how — that's beyond my brief. But yeah, we've been doing it piecemeal, and then a couple of months ago, the management said, 'Can we?' So, yeah. I've been recording that with a view to it coming out in some format at some point. But who knows when?... There also are future plans for some live film of us playing in various places. There's an ongoing thread.

January 19: Decree establishing internal rules and organization of work in prisons designated for individual confinement. March 27: Law amending Article 317 of the Penal Code regarding abortion. June 19: Law amending various articles of the Civil Code concerning adoption. June 29: Decree regulating the service and rules of prisons for communal confinement. November 12: Decree regulating gambling clubs: women are prohibited from entering. 1924

=== 4. Periodontal ligament === The periodontal ligament is the principal connective tissue structure anchoring the tooth to the surrounding alveolar bone. During clinical attachment loss, the collagen fiber bundles are progressively destroyed. The most apical extent of the remaining periodontal ligament shifts downward along the root surface, corresponding directly to the measured level of clinical attachment loss.

The spleen initially becomes noticeably swollen, but the lack of a healthy blood flow through the organ culminates in scarring of the spleen tissues and eventually death of the organ, generally before the age of 5 years. The actual anaemia of the illness is caused by haemolysis, the destruction of the red cells, because of their shape. Although the bone marrow attempts to compensate by releasing new red cells, the rate of destruction exceeds this. Healthy red blood cells typically function for 90–120 days; however, sickled cells only last 10–20 days. The rapid breakdown of RBCs in sickle cell disease results in the release of free heme into the bloodstream, exceeding the body's protective mechanisms. Although heme is an essential component of haemoglobin, it is also a potent oxidative molecule. Free heme is also an alarmin – a signal of tissue damage or infection, which triggers defensive responses in the body and increases the risk of inflammation and vaso-occlusive events.

Cohen (1952), former co-owner of the Boston Celtics and the Brooklyn Nets; former chairman and CEO of the Madison Square Garden Corporation Lawrence K. Grossman (1952), president of PBS 1976–1984 and NBC News 1985–1988 Richard Wald (1952), former president of NBC News 1973–1977 Robert A. Belfer (1955), oilman and philanthropist, namesake of the Belfer Center for Science and International Affairs at Harvard University Thomas Ludlow Chrystie II (1955), first chief financial officer of Merrill Lynch & Company and creator of the Cash Management Account Alfred Lerner (1955), chairman of MBNA Bank and ex-owner of the Cleveland Browns Richard Ravitch (1955), chairman of the Metropolitan Transportation Authority and the Bowery Savings Bank Sid Sheinberg (1955), head of Universal Pictures Barry F. Sullivan (1955), chairman and CEO of First Chicago Bank, deputy mayor of New York City under David Dinkins Edward Botwinick (1956), IT entrepreneur and inventor, co-founder of Timeplex Franklin A. Thomas (1956), former president of The Ford Foundation James R. Barker (1957), chairman of Interlake Steamship Company, former chairman and CEO of Moore-McCormack Peter L.

Sources: en.wikipedia.org

Frequently asked questions

How are the two variants distinguished in a laboratory?

The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.

Can the peptide lose potency in solution?

Yes. Degradation proceeds faster once the powder is dissolved, especially at room temperature or after multiple freeze and thaw cycles. Working solutions are often aliquoted to avoid repeated handling. Lyophilized powder held cold and dry retains its properties far longer.

Why does a purity trace sometimes show extra peaks?

Truncated sequences, oxidized residues and aggregated forms can all elute near the main peak. Reversed phase chromatography resolves many of these species, so the number of peaks is a useful indicator of synthesis quality. A single peak does not by itself prove correct sequence, which is why mass confirmation is paired with it.

Is CJC-1295 a natural hormone?

No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.

Network